Vertex Ventures HC (VVHC), a women-led global healthcare investment firm, has launched its third and largest fund, Fund III, with $200 million. The fund will focus on backing life sciences and medical technology companies that aim to drive innovation and improve patient outcomes.
Vertex Ventures HC has launched its third and largest fund, with $200 million, to invest in life sciences and medical technology companies focused on innovation and improving patient outcomes.
The fund will prioritize early-stage companies with disruptive technologies, breakthrough research, and a clear path towards developing new medicines for patients.
VVHC has a track record of investing in over 25 portfolio companies, including clinical-stage assets and FDA-cleared products, to bring transformative therapies and healthcare technologies to patients.